Cervical Cancer

Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy designed to increase the immune system’s ability to detect and fight tumor cells.

Antibody-drug conjugates (ADCs) revolutionize cancer therapy by delivering powerful drugs directly to tumors and minimize damage to healthy cells.

Durvalumab plus carboplatin and paclitaxel, continued with durvalumab monotherapy, decreased the risk of disease progression or death by 58%.

In 2014, the cobas human papillomavirus test was approved by the FDA for first-line, primary screening in women aged 25 years and older.

Tisotumab vedotin-tftv is the first antibody-drug conjugate to demonstrate positive overall survival data in patients with previously treated recurrent or metastatic cancer.

Merck will also conduct clinical trials in both males and females to evaluate the efficacy of a single dose of their current human papillomavirus vaccine compared with the approved 3-dose regimen.

Methods of treating cervical intraepithelial neoplasia are limited and invasive. The need for better treatments is clear; however, there are several promising therapies under development.

Previously, the study met the other primary endpoint of progression free survival, showing statistically significant and clinically meaningful improvements compared to chemoradiotherapy alone.

The approval was based on the results of a phase 3 trial that found an improvement in progression-free survival among individuals treated with pembrolizumab.

The accepted sBLA comes after phase 3 clinical trial results which demonstrated better overall survival, progression-free survival, and confirmed overall response rate than chemotherapy in patients with cervical cancer.

Understanding the recommended ages for vaccination is crucial to properly advise patients and parents who have questions

The approval of pembrolizumab with brachytherapy could aid individuals who were newly diagnosed with progressive cervical cancer.

Combining strong evidence-based recommendations with caring, compassionate, and frequent counseling opportunities hopefully will increase vaccine acceptance and ultimately reduce the incidence of HPV and associated cancers among our patients.

Cases of certain HPV-related high-grade disease were not found in the 10-year follow up for girls and boys who received 3 doses of the Gardasil 9 injection.

In addition to overall survival, main efficacy outcomes, such as progression-free survival, objective response rate, and time to response, were compared to chemotherapy alone.

Adding human papillomavirus genotypes to the predictive model had a significantly higher effect in improving accuracy compared to adding epidemiological factors and pelvic examination.

Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.

The 2023 ASCO Annual Meeting is being held in Chicago, Illinois from June 2 to 6.

Even before the Dobbs ruling overturned country-wide reproductive rights, the oncology field was already facing a dearth of maternal care access challenges.

Including the ThinPrep Pap Test improves access to the benefits of the human papillomavirus (HPV) assay, which is the only FDA-approved assay that tests for an extended set of HPV types individually.

Approval of a novel antibody-drug conjugate ushers in new second-line option.

Researchers question screening guidelines for older women after findings.

Despite significant advances in cancer treatment, molecular sequencing and enrollment of Black patients in clinical trials are still less than that of White and Asian patients.

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Overall rates of early-stage cervical cancer in the United States have been falling, but cases with advanced disease are continuing to rise.

Receiving a human papillomavirus vaccine and local surgical treatment could reduce the risk of recurring cervical lesions by 57%.

Studies suggest novel immunotherapy may have efficacy as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.

Bevacizumab-maly (Almysys; mAbxience) is the third biosimilar of bevacizumab (Avastin) approved in the United States.

Numbers have remained below prepandemic levels.

The death rate from cervical cancer has dropped by more than 50% since 1975.